FDA has recently approved an application that permits B Braun Medical (B Braun) to deliver approved 1g and 2g Cefepime for Injection USP and Dextrose Injection USP in B Braun's Duplex Drug Delivery System.

According to the FDA, Cefepime should be used only to treat or prevent bacterial infections in hospitals and healthcare centers. And especially, the infections that are proven or strongly suspected to be caused in the treatment of pneumonia, uncomplicated and complicated urinary tract infections, empiric therapy for febrile neutropenic patients, uncomplicated skin and skin structure infections, and complicated intra-abdominal infections are to be treated.

B Braun’s Duplex Drug Delivery System is a ready-to-use, two-compartment, flexible, eco-friendly IV container that stores pre-measured pharmaceuticals and diluent doses. Duplex is easy to stock as it can be stored at room temperature, with 18-month minimum dating, and fits in automated medication dispensing systems. Unit dose-based Duplex helps healthcare facilities achieve Joint Commission and USP Chapter < 797 > compliance that improves the practice of healthcare professionals while advancing patient safety.

B Braun Medical said that the healthcare workers administering 1g or 2g Cefepime through Duplex simply fold and squeeze the container and shake it to mix the pharmaceuticals and diluent. A barcode that references the final admixture, lot number and expiration date helps reduce medication errors, automate patient charting, track inventory and facilitate reimbursement tracking.

Rob Albert, vice president of marketing at B Braun Medical, said: “Making 1g and 2g Cefepime available to healthcare workers in B Braun’s Duplex Drug Delivery System gives them another weapon to combat challenging infections with speed, safety and accuracy.”